DEC 1 6 2004



FAX

То	1624	11110							
Company	Company USPTO								
Fax 🥞	03-872-9306								
From	Julie D. McFalls	11),							
Tel	919-483-1545	Fax 919-483-7988							
E-mail	Julie.D.McFalls@gsk.co	McFalls 3-1545 Fax 919-483-7988 McFalls@gsk.com er 16,2004 Pages including cover 15 lo.: 09/980,987							
Date	December 16,2004	Pages including cover 15							
Subject	Serial No.: 09/980,987								
	Julie D. McFalls 919-483-1545 Fax 919-483-7988 Julie D. McFalls@gsk.com December 16,2004 Pages including cover 15								

Giaxo Wallcome Inc. PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

Attached:

Certificate of Transmission
Fee Transmittal for FY 2005
Amendment
Terminal Disclaimer to Obviate A Double Patenting Rejection Over a Prior Patent

DEC 1 6 2004

P.2/15

CERTIFICATE OF Applicant(s): David CO	SIMILE (37 CFR 1.8)	Docket No. PU3611USw							
Application No. 09/980,987	Filing Date November 6, 2001	Examiner B. Coleman	Group Art Unit 1624						
Invention: 1,5-BENZODIAZEPINE DERIVATIVES									
I hereby certify that this	Fee Transı	nittal, Amendment, Terminal Disc	laimer						
	mitted to the United States Paten	(Identify type of correspondence) t and Trademark Office (Fax. No	·						
On December									
•		Julie D. McF (Typed or Printed Name of Person	alls Signing Certificate)						
		July D. M. Falls (Signature))						
	Note: Each paper must l	nave its own certificate of mailing.							
		•							
	•								

PTO/SB/17 (10-03)
Approved for use through 07/31/2008, OMB 0851-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. Complete if Known 09/980.987 **Application Number** for FY 2005 November 6, 2001 Filing Date David COLCLOUGH et al. Effective 10/01/2004. Patent fees are subject to annual revision. First Named Inventor B. Coleman Examiner Name Applicant claims small entity status. See 37 CFR 1.27 1624 **Art Unit** \$110.00 Attorney Docket No. PU3611USw TOTAL AMOUNT OF PAYMENT (\$) FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) 3. ADDITIONAL FEES Check Credit card Order Other None arge Entity | Small Entity Deposit Account: Fee Paid Fee **Fee Description** Code Code (\$) Deposit Account 65 Surcharge - late filing fee or oath 2051 1051 130 07-1392 25 Surcharge - late provisional filing fee or cover Number 2052 1052 50 Deposit **GlaxoSmithKline** Account Name 1053 130 Non - English specification 1053 130 1812 2,520 For filling a request for ex parte reexamination 1812 2,520 (check all that apply) The Director is authorized to: Requesting publication of SIR prior to Examiner 920 1804 920* Credit any overpayments Charge fee(s) Indicated below PCSION Requesting publication of SIR after Examiner Charge any additional fee(s) or any underpayment of fee(s) 1805 1.8401 1805 1.840* action Charge (ec(s) indicated below, except for the filling fee 55 Extension for reply within first month 1251 110 2251 to the above identified deposit account. 215 Extension for reply within second month 1252 430 2252 FEE CALCULATION 490 Extension for reply within third month 1253 950 2253 1. BASIC FILING FEE 765 Extension for reply within fourth month 2254 1254 1.530 arge Entity I Small Entity Extension for reply within fifth month 2255 1255 2.080 Fee Fee Code (\$) Fee Description Fee Paid Code (\$) 170 Notice of Appeal 1401 340 2401 2001 395 Utility filing fee 790 170 Filing a brief in support of an appeal 1001 1402 340 2402 2002 175 Design filing fee 1002 350 150 Request for oral hearing 1403 300 2403 2003 275 Plant filing fee 1003 1,510 Petition to Institute a public use proceeding 550 1451 1.510 1451 2004 395 Relssue filing fee 1004 790 55 Petition to revive - unavoidable 2452 1452 110 80 Provisional filing fee 1005 160 2005 685 Petition to revive - unintentional 1453 1,370 2453 SUBTOTAL (1) (\$) 665 Utility Issue fee (or relsaue) 2501 1501 1,370 2. EXTRA CLAIM FEES FOR UTILITY AND 245 Design issue fee 490 2502 1502 ee from below Fog Paid 2503 330 Plant issue fee Extra Claims 1503 660 0.00 130 Petitions to the Commissioner -20°° = ল Total Claims 1460 1460 130 0.00 50 Processing fee under 37 CFR § 1.17(q) independent Claime . 3** = ol X 50 1807 1807 Multiple Departent Submission of Information Disclosure 1806 1806 160 180 arge Entity | Small Entity Fee Description Recording each patent assignment per property (times number of properties) 40 Fee Fee Code (\$) 40 8021 Fee Fee Code (\$) 8021 Filing a submission after final rejection (37 CFR § 1.129(a)) Claims in excess of 20 385 790 2809 18 2202 9 1809 1202 For each additional invention to be examined (37 CFR § 1.129(b)) Independent claims in excess of 3 88 2201 44 1201 2610 1810 790 Multiple dependent claim, if not paid 2203 150 300 1203 Request for Continued Examination (RCE) 395 1801 780 2801 Reissus independent claims 66 2204 1204 Request for expedited examination of a design application over original patent 900 1502 1602 ** Reissue claims in excess of 20 18 2205 1205 110.00 and over original patent Other fee (specify) Terminal Disclaimer 50.00 SUBTOTAL (2) (\$) SUBTOTAL (3) \$110.00 (\$) *Reduced by Basic Filing Fee Paid or number previously paid, if greater, For Relssues, see above Complete (if applicable) SUBMITTED B' 919 483-1577 Registration No. Telephone 2K.209 Bonnie L. Deppenbrock (Altorney/Agent) Name (Print/Type Date December 16,2004 Signature

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete under the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/17 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Patent and Information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid of the control in the Complete if Known														
FEE TRANSMITTAL				ᄔ										
				▔▐	Application Number			er	09/980,9					
for FY 2005				_	Filing Date			╌┼	November 6, 2001					
Effective 10/01/2004. Patent fees are subject to annual revision.					n.				itor .	David COLCLOUGH et al.				
Applicant claims small entity status. See 37 CFR 1.27					Examiner Name			_	B, Coleman					
				Art Unit			-+	1624	***					
TOTAL AMOUNT OF PAYMENT (\$) \$110				.00 Attorney Docket No.				10.	PU36111	USW				
WE				FE	E CA	LCULAT	TON (cont	inued)						
METHOD OF PAYMENT (check all that apply) Chack Credit card Money Other None 3. ADD														
Chack L		_	∼ اسا ′Order اسا		Large F		<u>Şmail '</u> Fee	<u>Enlity.</u> Fee	٠.	Foo D	escription	ı	•	Fee Paid
Deposit [Code	(\$)	Code	(\$) 65	Surch		iling fee of 6:		,	
Account Number			07-1392		1051	130	2051 2052				provisional fil		cover	
Deposit [lino	1052	50			sheet			-	'	
Account Name		<u> </u>	axoSmithK	Mite	1053	130	1053			English spe		a raavamin	ation	
The Director is	sauthort	tzed to:	(check all the	(apply)		2,520	1812				st for ex parte ation of SIR			
Charge fee	(s) Indica	aled below		iny overpayments	1804	9201	1804		action)				
			r any underpayme		1805	1.840*	1605 1	,540*	Reque	esting public 1	cation of SIR	alter Exam	niner	<u></u> _
Charge fee(s) indicated below, except for the filling fee			1251	110	2251		Exten	gion for repl	ly within first					
to the above lde				1	1252	430	2252	215			ly within seco			
	_		LCULATION		1253	980	2253	480			ly within thin			
1. BASK					1254	1,530	2254	765			ly within four			<u> </u>
Large Entity Fee Fee	B Fee	Fee F	ee Description	Fee Paid	1255	2,080	2255	1.040			dy within fifth	month		
Code (\$)			Hility filing fee	Tee Taid	1401	340	2401	170		e of Appeal				
1001 790 1002 350			esign filing fee		1402	340	2402	170	_		upport of an	appeai		
1002 350 1003 550	T		lant (lling fee		1403	300	1	150		est for oral l			lina	
1004 790	-		teissue filing fee		1451	-					te a public u: - unavoidab		a	
1005 160	2005	80 F	Suill laudiekov	fee	1452		1				- unintentior			
SUBTOTAL (1) (\$)					1.370				y îssue fee (
2 FYTD	A CLA	IM FEE	S FOR UTIL	TY AND	1501	1,370 2 490	1	245		gn Issue fee				
		Extra Cla	,	ee from below Fee Paid				330		l issue fee				
Total Glaims		= xtra Cia 7 -20** =		= 0.00				130			Commissione	3 r		
Independent] - 3** -		=	1607		1	50		essing fee u	ınder 37 CFF	R § 1,17(d	7)	
Claims Multiple Dep	endent				1806		1		Subr	nission of In	oformation Di			
Large Entit			Fee Desc	ription	1			40	State Reco	ement endina each	palent assig	nment per	property	
Fee Fe Code (\$		le (5)		•	ē02°				(time	s crupper c	or properties)		-	
1202 18			Claims in exces		1809	9 790	2809	395	(37 (CFR § 1.12	lon after fina 29(a))			
1201 86	- I			ims in excess of 3	1810	790	2810	395	For 6	each additio	nal Inventior 29(b))	to be exa	mined	
1203 30			** Reissue inde	lent claim, If not paid pendent claims	180	1 79	2801		Req	uest for Cor	ntinued Exen		CE)	
1204 8	8 2204	4 44	over outing t	Jetent	180		0 1802		Req	uest for exp	edited exam	ination		
1205 1	8 220	5 9	** Reissue clair and over origi	ns in excess of 20 inal palent			(specify) <u>Ter</u>		design appl Disclalmer	السائيان			110.00
SUBTOTAL (2) (\$) \$0.00						_			_ =	noid.	SUBTOT	AL (3)	(\$)	\$110.00
⇔or number	*Reduced by Basic Filing Fee Faio								4,					
SUBMIT		_					1 -4				Complete (f applicable)		
Name (Prir			Bonnie L	Deppenbrock	*		tration Neg/Agent		21	9,209	Telephoné		919 483-	1577
<u> </u>			1 .	I. Rena		<u> </u>	1				Date	Derem	her 16	,2004
Signature			Some mer	L. KILDER		1-116-	<u> </u>				ation sho			

WARNING: Information on this form may become public. Credit card information sho not be included on this form. Provide credit card Information and authorization on

This collection of Information is required by 37 CFR 1.17 and 1.27. The Information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, use the uspect of the complete application from the USPTO. Time will vary depending upon the Individual case. Any comments including gathering, preparing, and submitting the complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of line you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS and 1970 All (Exchange Changes) and Insulation and I

PU3611USw

DEC 1 6 2004

CEL:

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David Colclough et al.

Application Serial No.:

09/980,987

Art Unit: 1624

Filing Date:

November 6, 2001

Examiner: B. Coleman

Title:

1,5-BENZODIAZEPINE

DERIVATIVES

Commissioner for Patents Washington, D.C. 20231

AMENDMENT

Sir:

This amendment is responsive to the Office Action mailed September 28, 2004. Please amend the application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2.

Remarks/Arguments begin on page 7.